Pegcetacoplan (2 brand names, 1 dosage form, 2 routes)
Available dosage forms: SOLUTION.
Routes of administration: SUBCUTANEOUS, INTRAVITREAL.
Brand Names
- EMPAVELI
- SYFOVRE
Indications and Usage
SYFOVRE is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Adverse Reactions
The following clinically significant adverse reactions are described elsewhere in the labeling: Ocular and periocular infections [see Contraindications (4.1)] Active intraocular inflammation [see Contraindications (4.2)] Hypersensitivity [see Contraindications (4.3)] Endophthalmitis and retinal detachments [see Warnings and Precautions (5.1)] Retinal Vasculitis and/or Retinal Vascular Occlusion [see Warnings and Precautions (5.2)] Neovascular AMD [see Warnings and Precautions (5.3)] Intraocular inflammation [see Warnings and Precautions (5.4)] Increased intraocular pressure [see Warnings and Precautions (5.5)]
Mechanism of Action
Pegcetacoplan binds to complement protein C3 and its activation fragment C3b with high affinity thereby regulating the cleavage of C3 and the generation of downstream effectors of complement activation